Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine versus varenicline for smoking cessation through Quitline services
ACTRN12616001654448Phase 3Active, not recruiting
- Sponsor
- University of New South Wales
- Start
- Nov 2017
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in nicotine dependence comparing Cytisine arm with Varenicline arm (2 arms). Primary endpoint: Carbon monoxide validated continuous abstinence. Started Nov 2017; status: active, not recruiting.
02
Drugs
cytisiniclinevarenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on ACTRN12616001654448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001654448.